Artificial intelligence in healthcare sits at the intersection of powerful software and real human need, at a time when energy shocks, uneven inflation and shifting bond markets keep wider assets on edge. While global growth expectations are softer and policy signals are mixed, AI tools that can help clinicians detect disease, personalise treatment and run hospitals more efficiently still speak to long term structural demand. This Transformative AI Healthcare screener is built to surface companies linked to those trends. In this article, you will see 3 stocks from the screener that stand out for further research.

Olympus (TSE:7733)

Overview: Olympus is a long established Japanese medtech company that builds endoscopy and surgical imaging systems used in hospitals worldwide, from gastrointestinal and respiratory procedures to urology, gynecology and ear, nose and throat surgery, alongside related devices, software and servicing.

Operations: Olympus generates the bulk of its revenue from Gastrointestinal Solutions at ¥630,099m and Surgical & Interventional Solutions at ¥357,254m, with sales spread across North America, Europe, Japan, China and the rest of Asia and Oceania.

Market Cap: ¥1.78t

For investors who want exposure to AI in real world clinical workflows rather than pure software plays, Olympus may warrant a closer look. The group is reshaping itself around two core divisions and rolling out platforms such as the VISERA ELITE III surgical imaging system, along with cloud based and AI assisted endoscopy tools. Analysts have noted expectations for earnings growth that outpaces the broader Japan market, together with a 1.86% dividend. At the same time, recent earnings guidance cuts, execution risk in China and elevated R&D spending keep pressure on management to deliver. For investors interested in the mix of AI adoption, global medtech scale and active capital allocation decisions, there is more to explore in the full story.

Olympus is reshaping around AI powered endoscopy and surgical imaging, yet recent guidance cuts and higher R&D spend raise fresh questions. Get the analysis report for Olympus to see what might be hiding behind the headline story.

eWeLLLtd (TSE:5038)

Overview: eWeLLLtd runs a suite of cloud tools that help Japan’s home based nursing providers handle everyday work, from electronic medical records and insurance claims to staff attendance, admin support, AI assisted visit reports, factoring of receivables and e learning for legal training.

Market Cap: ¥32.27b

eWeLLLtd operates at the intersection of healthcare, software and AI, with its iBow platform helping visiting nurses reduce paperwork and capture richer clinical data through AI powered reporting. Earnings and revenue forecasts in the available data point to growth that outpaces the wider Japanese market, supported by a 32.2% ROE and net margins above 30%, which together indicate that the core business is currently highly profitable. At the same time, a premium P/E multiple, full reliance on higher risk external borrowing and only 25% board independence introduce governance and funding questions that careful investors may want to weigh. For those tracking how AI is reshaping home care and what that could mean for long term returns, the finer details may matter more than the headline growth rates.

High margins and 32.2% ROE suggest eWeLLLtd’s home nursing platform might be doing more than the current P/E is letting on. At the same time, the reliance on external borrowing and governance mix hint at a twist in the analysis report for eWeLLLtd

FINDEX (TSE:3649)

Overview: FINDEX is a Tokyo based healthtech company that builds software and digital tools for hospitals and clinics, from image filing, electronic medical records and document automation to remote information sharing, AI generated medical text and workflow robots that cut routine admin work.

Operations: FINDEX generates most of its revenue from the Medical Business at ¥5,691m, with smaller contributions from the Public Sector Business at ¥355m and Health Tech Business at ¥63m, almost entirely in Japan where revenue totals about ¥6,109m.

Market Cap: ¥20.0b

FINDEX brings AI directly into day to day clinical work through tools like CocktailAI for medical text generation and DigiWorker for hospital automation, all on top of a long running medical records and imaging platform that currently supports net margins of 20.6%. Forecast earnings growth of 13.24% a year and historically high ROE above 23% are paired with a P/E that sits below many healthcare software peers. This can appeal to investors who want growth at a measured price. At the same time, full reliance on higher risk external borrowing and limited board independence mean the funding model and governance deserve closer attention as this healthtech stack expands across Japanese hospitals.

FINDEX pairs AI tools like CocktailAI and DigiWorker with ROE above 23% and a P/E below many healthcare software peers, yet funding and governance questions still linger in the background. Get the analyst forecasts for FINDEX to see how that tension could reshape the story from here.

The three companies here are just a starting point, and the full Transformative AI Healthcare Stocks screener has surfaced 5 more names with equally compelling AI healthcare narratives that could be worth your time. Identify the highest conviction ideas by using Simply Wall St to filter the Transformative Artificial intelligence (AI) Healthcare Stocks screener for the exact catalysts, financial traits and business stories that fit how you want to invest.

Take Control of Your Investment Journey

If FINDEX or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your top picks to a Watchlist to monitor the share price against the fair value for the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before They Fly?

Fresh ideas do not stay under the radar for long, and momentum can shift quickly once the crowd catches on, so scan these curated picks now and consider them while they are still early.

• Identify cash rich contenders that could be better positioned to navigate shocks by reviewing our curated list of solid balance sheet and fundamentals (34 results) and see which names still look robust while it matters.
• Monitor metal producers that might benefit if sentiment turns toward hard assets by checking the hand picked 29 elite gold producer stocks before any renewed strength is fully reflected in prices.
• Explore next generation automation trends ahead of slower money by shortlisting opportunities from the carefully filtered 35 robotics and automation stocks while these stories are still taking shape.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.